{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:07:18Z","timestamp":1793164038067,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SLC25A10, the mitochondrial dicarboxylate carrier, plays a crucial role in mitochondrial metabolism and protects against liver lipotoxicity. Moreover, its frequent amplification or mutation in cancers, particularly hepatocellular carcinoma (HCC), correlates with a poor prognosis. This study aimed to investigate the role of SLC25A10 in chemotherapy resistance in HCC and elucidate the underlying mechanisms. In this study, we found that hypoxia increased SLC25A10 expression with a preferential shift toward isoform 3 in HCC. This isoform interacts with the nuclear transporter IPO7 to translocate into the nucleus, where it binds to transcription factor CEBPB. This interaction upregulates the transcription of the anti-apoptotic gene\n                    <jats:italic>BCL2A1<\/jats:italic>\n                    , thereby enhancing HCC cell resistance to the chemotherapeutic agent, etoposide. Notably, disruption of the SLC25A10 isoform 3-IPO7 interaction significantly sensitized HCC tumors to etoposide in vivo, suggesting that targeting this interaction could be a promising therapeutic strategy to improve chemotherapy efficacy in HCC. This study reveals a novel nuclear function of the mitochondrial dicarboxylate carrier SLC25A10 in transcriptional regulation under hypoxic conditions, distinct from its canonical mitochondrial role. These findings expand our understanding of SLC25A10 biology and uncover a previously unrecognized mechanism that drives hypoxia-induced chemoresistance in HCC. Our findings suggest that SLC25A10 is a potential therapeutic target to overcome drug resistance in HCC.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08667-4","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:56:30Z","timestamp":1775724990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nuclear translocation of SLC25A10 isoform 3 promotes chemoresistance in HCC cells via CEBPB\/BCL2A1 signaling"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-8638","authenticated-orcid":false,"given":"Dan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1321-2570","authenticated-orcid":false,"given":"Shuang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5788-3965","authenticated-orcid":false,"given":"Jun","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"8667_CR1","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1042\/bj3440953","volume":"3443","author":"G Fiermonte","year":"1999","unstructured":"Fiermonte G, Dolce V, Arrigoni R, Runswick MJ, Walker JE, Palmieri F. Organization and sequence of the gene for the human mitochondrial dicarboxylate carrier: evolution of the carrier family. Biochem J. 1999;3443:953\u201360.","journal-title":"Biochem J"},{"key":"8667_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1042\/bj1340769","volume":"134","author":"RN Johnson","year":"1973","unstructured":"Johnson RN, Chappell JB. The transport of inorganic phosphate by the mitochondrial dicarboxylate carrier. Biochem J. 1973;134:769\u201374.","journal-title":"Biochem J"},{"key":"8667_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10545-014-9708-5","volume":"37","author":"F Palmieri","year":"2014","unstructured":"Palmieri F. Mitochondrial transporters of the SLC25 family and associated diseases: a review. J Inherit Metab Dis. 2014;37:565\u201375.","journal-title":"J Inherit Metab Dis"},{"key":"8667_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00424-003-1099-7","volume":"447","author":"F Palmieri","year":"2004","unstructured":"Palmieri F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflug Arch. 2004;447:689\u2013709.","journal-title":"Pflug Arch"},{"key":"8667_CR5","doi-asserted-by":"publisher","first-page":"32434","DOI":"10.1074\/jbc.M503152200","volume":"280","author":"S Mizuarai","year":"2005","unstructured":"Mizuarai S, Miki S, Araki H, Takahashi K, Kotani H. Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem. 2005;280:32434\u201341.","journal-title":"J Biol Chem"},{"key":"8667_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jhep.2021.03.006","volume":"75","author":"YA An","year":"2021","unstructured":"An YA, Chen S, Deng Y, et al. The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol. 2021;75:387\u201399.","journal-title":"J Hepatol"},{"key":"8667_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.redox.2017.08.022","volume":"14","author":"A Baulies","year":"2018","unstructured":"Baulies A, Montero J, Matias N, et al. The 2-oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading. Redox Biol. 2018;14:164\u201377.","journal-title":"Redox Biol"},{"key":"8667_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2018.09.002","volume":"439","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek J, Ritter V, Wirsdorfer F, Klein D, Jendrossek V, Matschke J. Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia. Cancer Lett. 2018;439:24\u201338.","journal-title":"Cancer Lett"},{"key":"8667_CR9","doi-asserted-by":"publisher","first-page":"9271","DOI":"10.18632\/oncotarget.3375","volume":"6","author":"X Zhou","year":"2015","unstructured":"Zhou X, Paredes JA, Krishnan S, Curbo S, Karlsson A. The mitochondrial carrier SLC25A10 regulates cancer cell growth. Oncotarget. 2015;6:9271\u201383.","journal-title":"Oncotarget"},{"key":"8667_CR10","doi-asserted-by":"publisher","first-page":"111855","DOI":"10.1016\/j.cellsig.2025.111855","volume":"132","author":"J Feng","year":"2025","unstructured":"Feng J, Zhao M, Chen Z, et al. STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: a novel therapeutic target. Cell Signal. 2025;132:111855.","journal-title":"Cell Signal"},{"key":"8667_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.4103\/1008-682X.154310","volume":"17","author":"KL Loveland","year":"2015","unstructured":"Loveland KL, Major AT, Butler R, Young JC, Jans DA, Miyamoto Y. Putting things in place for fertilization: discovering roles for importin proteins in cell fate and spermatogenesis. Asian J Androl. 2015;17:537\u201344.","journal-title":"Asian J Androl"},{"key":"8667_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26125-x","volume":"12","author":"KA Gajewska","year":"2021","unstructured":"Gajewska KA, Lescesen H, Ramialison M, Wagstaff KM, Jans DA. Nuclear transporter Importin-13 plays a key role in the oxidative stress transcriptional response. Nat Commun. 2021;12:5904.","journal-title":"Nat Commun"},{"key":"8667_CR13","doi-asserted-by":"publisher","first-page":"e14714","DOI":"10.1016\/j.heliyon.2023.e14714","volume":"9","author":"YX Zhao","year":"2023","unstructured":"Zhao YX, Yang Z, Ma LB, Wang F, Wang Y, Xiang C. HIF1A overexpression predicts the high lymph node metastasis risk and indicates a poor prognosis in papillary thyroid cancer. Heliyon. 2023;9:e14714.","journal-title":"Heliyon"},{"key":"8667_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05473-6","volume":"13","author":"Z Niu","year":"2022","unstructured":"Niu Z, Fan J, Chen F, et al. RBCK1 regulates the progression of ER-positive breast cancer through the HIF1alpha signaling. Cell Death Dis. 2022;13:1023.","journal-title":"Cell Death Dis"},{"key":"8667_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","volume":"69","author":"J Schodel","year":"2016","unstructured":"Schodel J, Grampp S, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69:646\u201357.","journal-title":"Eur Urol"},{"key":"8667_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27944-8","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Lu H, Chen C, Lyu Y, Cole RN, Semenza GL. HIF-1 interacts with TRIM28 and DNA-PK to release paused RNA polymerase II and activate target gene transcription in response to hypoxia. Nat Commun. 2022;13:316.","journal-title":"Nat Commun"},{"key":"8667_CR17","doi-asserted-by":"crossref","unstructured":"Zhang J, Qin Y, Martinez M et al. HIF-1alpha and HIF-2alpha redundantly promote retinal neovascularization in patients with ischemic retinal disease. J Clin Invest 2021;131:e138301.","DOI":"10.1172\/JCI139202"},{"key":"8667_CR18","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-20-2876","volume":"81","author":"Z Liu","year":"2021","unstructured":"Liu Z, Sun L, Cai Y, et al. Hypoxia-induced suppre:ssion of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1. Cancer Res. 2021;81:1265\u201378.","journal-title":"Cancer Res"},{"key":"8667_CR19","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s00018-019-03387-9","volume":"77","author":"JP Tolonen","year":"2020","unstructured":"Tolonen JP, Heikkila M, Malinen M, et al. A long hypoxia-inducible factor 3 isoform 2 is a transcription activator that regulates erythropoietin. Cell Mol Life Sci. 2020;77:3627\u201342.","journal-title":"Cell Mol Life Sci"},{"key":"8667_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman A, Choo XY, Chew G, et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat Commun. 2021;12:3015.","journal-title":"Nat Commun"},{"key":"8667_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40291-021-00570-2","volume":"26","author":"S Atout","year":"2022","unstructured":"Atout S, Shurrab S, Loveridge C. Evaluation of the suitability of RNAscope as a technique to measure gene expression in clinical diagnostics: a systematic review. Mol Diagn Ther. 2022;26:19\u201337.","journal-title":"Mol Diagn Ther"},{"key":"8667_CR22","doi-asserted-by":"publisher","first-page":"114344","DOI":"10.1016\/j.bios.2022.114344","volume":"211","author":"L Zhang","year":"2022","unstructured":"Zhang L, Parvin R, Fan Q, Ye F. Emerging digital PCR technology in precision medicine. Biosens Bioelectron. 2022;211:114344.","journal-title":"Biosens Bioelectron"},{"key":"8667_CR23","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.21037\/tcr-2024-2319","volume":"14","author":"YH Ding","year":"2025","unstructured":"Ding YH, Huang TY, Xu SM, et al. Inhibition of SLC25A10 promotes cellular senescence and impedes hepatocellular carcinoma progression. Transl Cancer Res. 2025;14:4939\u201354.","journal-title":"Transl Cancer Res"},{"key":"8667_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41420-025-02528-3","volume":"11","author":"G Yu","year":"2025","unstructured":"Yu G, Chen K, Xu B, Cao Q. Mitochondrial SLC25A10 promotes prostate cancer progression by inhibiting ferritinophagy. Cell Death Discov. 2025;11:242.","journal-title":"Cell Death Discov"},{"key":"8667_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41420-025-02712-5","volume":"11","author":"C Ma","year":"2025","unstructured":"Ma C, Lu X, Ni C, et al. SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer. Cell Death Discov. 2025;11:447.","journal-title":"Cell Death Discov"},{"key":"8667_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.sbi.2016.12.009","volume":"44","author":"AD Cunningham","year":"2017","unstructured":"Cunningham AD, Qvit N, Mochly-Rosen D. Peptides and peptidomimetics as regulators of protein-protein interactions. Curr Opin Struct Biol. 2017;44:59\u201366.","journal-title":"Curr Opin Struct Biol"},{"key":"8667_CR27","doi-asserted-by":"publisher","first-page":"116878","DOI":"10.1016\/j.ejmech.2024.116878","volume":"279","author":"D Han","year":"2024","unstructured":"Han D, Li A, Zhu L, Zhuang C, Zhao Q, Zou Y. Peptide inhibitors targeting Ras and Ras-associated protein-protein interactions. Eur J Med Chem. 2024;279:116878.","journal-title":"Eur J Med Chem"},{"key":"8667_CR28","doi-asserted-by":"publisher","first-page":"103641","DOI":"10.1016\/j.drudis.2023.103641","volume":"28","author":"S Kongsamut","year":"2023","unstructured":"Kongsamut S, Eishingdrelo H, Modulating GPCR. and 14-3-3 protein interactions: prospects for CNS drug discovery. Drug Discov Today. 2023;28:103641.","journal-title":"Drug Discov Today"},{"key":"8667_CR29","doi-asserted-by":"publisher","first-page":"114097","DOI":"10.1016\/j.addr.2021.114097","volume":"182","author":"S Haddadzadegan","year":"2022","unstructured":"Haddadzadegan S, Dorkoosh F, Bernkop-Schn\u00fcrch A. Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers. Adv Drug Deliv Rev. 2022;182:114097.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08667-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08667-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:36:25Z","timestamp":1779208585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08667-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8667"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08667-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures for animals were approved by the Institutional Animal Care and Use Committee of the Shanghai Jiao Tong University (IACUC protocol no. JUMC2023-023-A) and conducted in accordance with the AAALAC guidelines. The study involving human participants was approved by the Institutional Review Board (IRB approval no. 2020 (172)) of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent was obtained from all patients prior to sample collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"491"}}